Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Endothelin antagonism reduces hemoglobin A1c in patients with pulmonary hypertension

Canadian Journal of Physiology and Pharmacology(2022)10.1139/cjpp-2022-0132Source: DataRank Database

Endothelin antagonism reduces hemoglobin A1c in patients with pulmonary hypertension is a dataset published in Canadian Journal of Physiology and Pharmacology (2022). On theSindex it has a DataRank of 0.480, placing it in the top 39.8% of the data-sharing corpus. It has been cited 10 times, with 2 citing works in its 1-hop citation network.

Top 40%percentile

0.480DataRank

Ranks in the top 40% for downstream scientific impact

Data paper Open Access10 citations · 2 citing works in its network

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 1.10)OA: bronzeTopics (53)Linked Datasets (8)DataCite Reuse (8)IDs (PubMed, PMC, OpenAlex)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (1/3)

Dataset classification

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 75%Citation Network 25%

Base Score Contribution

0.360

From this paper's citation signal

Citation Network Contribution

0.120

From 2 citing papers with measurable signal

Learn more about DataRank methodology →

Top 2 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 2 citers.

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
Cardiovascular Diabetology202327 citations27 referencesContributes 0.123
Use of Epic Electronic Health Record System for Health Care Research: Scoping Review
Journal of Medical Internet Research202399 citations257 referencesContributes 0.018

Authors (3)

Joshua S. Speed ORCID,John S. Clemmer ORCID,Jennifer Stapel

Live enrichment

PubMed:35658576 PMC:PMC9851169 OpenAlex:https://openalex.org/W4281734870

NIMHD NIH HHS

Grant: K99 MD014738

NIGMS NIH HHS

Grant: P20 GM104357

NIDDK NIH HHS

Grant: R01 DK124327

NHLBI NIH HHS

Grant: R00 HL127178

National Institutes of Health

Grant: 4P20GM104357-04

Cadiorenal and Metabolic Diseases Research Center

National Institutes of Health

Grant: 5R00HL127178-04

Endothelin - Mechanisms in Hypertension and Obesity

National Institutes of Health

Grant: 1R01DK124327-01A1

Endothelin-1 in Obesity and Insulin Resistance

National Institutes of Health

Grant: 5K99MD014738-02

Improving Hypertension Treatment in African Americans Using Computational Modeling and Predictive Analytics

FWCI

1.10

Citation Percentile

0.8%

Citation Trend

2023

2024

bronzeLicense: CSP TDM

journalhttps://cdnsciencepub.com/doi/pdf/10.1139/cjpp-2022-0132

publisherhttps://cdnsciencepub.com/doi/pdf/10.1139/cjpp-2022-0132

publisherhttps://cdnsciencepub.com/doi/full-xml/10.1139/cjpp-2022-0132

journalhttps://doi.org/10.1139/cjpp-2022-0132

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35658576

Fields of Study

Nitric Oxide and Endothelin EffectsCardiovascular Function and Risk FactorsPulmonary Hypertension Research and Treatments0301 basic medicine0303 health sciences03 medical and health sciencesAnimalsBlood GlucoseDiabetes Mellitus, Type 2Endothelin Receptor AntagonistsEndothelinsGlycated HemoglobinHypertension, PulmonaryHypoglycemic AgentsInsulinInsulin ResistanceMice

MeSH Terms

AnimalsBlood GlucoseDiabetes Mellitus, Type 2Glycated HemoglobinHypertension, PulmonaryHypoglycemic AgentsInsulinInsulin ResistanceEndothelinsMiceEndothelin Receptor Antagonists

Keywords

MedicineGlycemicInternal medicineBody mass indexDiabetes mellitusInsulin resistanceEndothelin receptorPopulationInsulinEndocrinologyReceptorGlucoseEndothelin-1Hba1cRésistance À L’insulineEndothéline 1Blood GlucoseEndothelin Receptor AntagonistsGlycated HemoglobinEndothelinsHypertension, PulmonaryMiceDiabetes Mellitus, Type 2AnimalsHypoglycemic Agents

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

10.6084/m9.figshare.26617858.v1figshare

Additional file 1 of Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

10.6084/m9.figshare.26617858figshare

Additional file 2 of Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

10.6084/m9.figshare.26617861.v1figshare

Additional file 2 of Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

10.6084/m9.figshare.26617861figshare

Additional file 3 of Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

10.6084/m9.figshare.26617864.v1figshare

Additional file 3 of Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

10.6084/m9.figshare.26617864figshare

Additional file 4 of Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

10.6084/m9.figshare.26617867.v1figshare

Additional file 4 of Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

10.6084/m9.figshare.26617867figshare